Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

Dr. Ou elaborates on the key takeaways from the IMpower150 study in non-small cell lung cancer (NSCLC) and whether the outcomes change how we treat post-EGFR patients

Published: 27 June 2018

Recent Videos

video

Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

Sharon Karlsberg, Principal, Oncology, ZS Associates, considers the future of CAR-T therapies with Michael R. Bishop, MD, Professor of Medicine, ...

video

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

Sharon Karlsberg, Principal, Oncology, ZS Associates, considers how manufacturers can help institutions prepare for CAR-T therapies with Michael R. Bishop, ...

video

How Can a CAR-T Center Get Established and Effectively Treat Patients?

Sharon Karlsberg, Principal, Oncology, ZS Associates, discusses how a CAR-T center becomes established and effectively treats patients with Michael R. ...

video

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

Dr. Ou considers whether Tumor Mutation Burden (TMB) is a valid biomarker in determining non-small cell lung cancer (NSCLC) patients ...

video

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

Dr. Ou provides opinion on whether he would continue pemetrexed maintenance after successful treatment of a patient with carboplatin, pemetrexed, ...

video

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

Dr. Ou elaborates on the key takeaways from the IMpower150 study in non-small cell lung cancer (NSCLC) and whether the ...

video

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

Dr. Ou offers opinion on how chemotherapy should be combined with immunotherapy in the treatment of 2nd line non-small cell ...

video

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

Dr. Ou discusses outcomes from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in the treatment of 1st ...

video

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

Dr. Ou offers opinion on whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and ...

video

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

Dr. Levy elaborates on whether Tumor Mutation Burden (TMB) is a valid biomarker to determine those non-small cell lung cancer ...

Related Videos

video-image

How Can a CAR-T Center Get Established and Effectively Treat Patients?

video-image

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

video-image

Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on testing for PD-L1 expression in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Novel Endpoints: Working Through Today's Challenges to Improve the Future of Cancer Care

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy